|
Clinical and serological characteristics of SSc patients |
||
| Characteristics |
Fibrotic (n = 10) |
Atrophic (n = 6) |
|
|
||
| Mean age (range) |
54 (39–72) |
58 (37–69) |
| Mean disease duration, months (range) |
11 (4–18) |
96 (36–168) |
| Male/female |
2/8 |
0/6 |
| Organ involvement |
||
| Mean skin score (range) |
33 (19–41) |
17 (11–24) |
| Oesophageal |
7/10 |
3/6 |
| Other gastrointestinal |
4/10 |
1/6 |
| Lung |
4/10 |
2/6 |
| Muscle |
3/10 |
0/6 |
| Renal |
2/10 |
1/6 |
| Cardiac |
0/10 |
1/6 |
| Pulmonary hypertension |
2/10 |
0/6 |
| Serology |
||
| Antinuclear |
10/10 |
6/6 |
| Anti-topoisomerase 1 |
4/10 |
3/6 |
| Anti-RNA polymerase I/III |
2/10 |
1/6 |
| Anti-nuclear RNP |
1/10 |
1/6 |
| Microvascular damage |
||
| Structural capillary damage |
10/10 |
6/6 |
|
RNP, ribonuclear protein; SSc, systemic sclerosis. | ||
Rajkumar et al. Arthritis Research & Therapy 2005 7:R1113 doi:10.1186/ar1790 |
||